Model-based analysis of costs and outcomes of non-invasive prenatal testing for Down's syndrome using cell free fetal DNA in the UK National Health Service

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Morris, Stephen ^a   Karlsen, Saffron ^a   Chung, Nancy ^b   Hill, Melissa ^c,d   Chitty, Lyn S ^c,d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF EXETER   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CELL FREE SYSTEM; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DNA DETERMINATION; DOWN SYNDROME; FEMALE; FETUS OUTCOME; GENETIC SCREENING; HEALTH SERVICE; HIGH RISK PREGNANCY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NON INVASIVE PROCEDURE; OUTCOME ASSESSMENT; PATIENT SAFETY; PREGNANCY OUTCOME; PREGNANT WOMAN; PRENATAL DIAGNOSIS; PRENATAL SCREENING; RISK ASSESSMENT; SPONTANEOUS ABORTION; UNITED KINGDOM; ABORTION, SPONTANEOUS; BLOOD; COST; ECONOMICS; MATERNAL AGE; MIDDLE AGED; PREGNANCY; STATISTICAL MODEL; YOUNG ADULT;

DNA;

ABORTION, SPONTANEOUS; ADOLESCENT; ADULT; COSTS AND COST ANALYSIS; DNA; DOWN SYNDROME; FEMALE; GREAT BRITAIN; HUMANS; MATERNAL AGE; MIDDLE AGED; MODELS, STATISTICAL; PREGNANCY; PRENATAL DIAGNOSIS; YOUNG ADULT;

EID: 84899508178     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093559     Document Type: Article

References (40)

1. NHS FASP. Screening for Down's syndrome: UK NSC policy recommendaations (2011) 2011-2014 Model of Best Practice. Exeter, United Kingdom: NHS Fetal Anomaly Screening Programme, UK National Screening Committee.
2. Tabor A, Alfirevic Z (2010) Update on procedure-related risks for prenatal diagnosis techniques. Fetal Diagn Ther 27: 1-7.
3. Lo YMD, Corbetta N, Chamberlain PF, Rai V, Sargent IL, et al. (1997) Presence of fetal DNA in maternal plsma and serum. Lancet 350: 485-487. (Pubitemid 27343304)
4. Boon EM, Faas BH (2013) Benefits and limitations of whole genome versus targeted approaches for non-invasive prenatal testing for fetal aneuploidies. Prenat Diagn 33: 563-568.
5. Ehrich M, Deciu C, Zweifellhofer T, Tynan JA, Cagasan L, et al. (2011) Non-invasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol 204; 205.e1-11.
6. Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, et al. (2011) DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 13: 913-920.
7. Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ on behalf of the MatErnal Blood IS Source to Accurately diagnose fetal aneuploidy (MELISSA) Study Group (2012) Genome-Wide Fetal Aneuploidy Detection by Maternal Plasma DNA Sequencing. Obstet Gynecol 119: 890-901.
8. Ashoor G, Syngelaki A, Wagner M, Birdir C, Nicolaides KH (2012) Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol 206: 322.e1-5.
9. Sparks AB, Struble CA, Wang ET, Song K, Oliphant A (2012) Non-invasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. Am J Obstet Gynecol 206: 319.e1-9.
10. Norton ME, Brar H, Weiss J, Karimi A, Laurent LC, et al. (2012) Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicentre prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol 207: 137.e1-8.
11. Futch T, Spinosa J, Bhatt S, de Feo E, Rava RP, et al. (2013) Initial clinical laboratory experience in non-invasive prenatal testing for fetal aneuploidy from maternal plasma DNA samples. Prenat Diagn 33: 569-574.
12. Liang D, Lv W, Wang H, Xu L, et al. (2013) Non-invasive prenatal testing of fetal whole chromosome aneuploidy by massively parallel sequencing. Prenat Diagn 33: 409-415.
13. ACOG Statement - The American College of Obstetricians and Gynecologists Committee on Genetics; The Society for Maternal-Fetal Medicine Publications Committee (2012) Committee Opinion. Obstet Gynecol 120: 1532-1534.
14. Benn PA, Borrell A, Cuckle H, Dugoff L, Gross S, et al. (2012) Prenatal detection of Down syndrome using massively parallel sequencing (MPS): a rapid response statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis, 24 October 2011. Prenat Diagn 32: 1-2.
15. Langlois S, Brock JA, Genetics Committee, Wilson RD, Audibert F, et al. (2013) Current status in non-invasive prenatal detection of down syndrome, trisomy 18, and trisomy 13 using cell-free DNA in maternal plasma. J Obstet Gynaecol Can 35: 177-181.
16. Antenatal Results and Choices (2013) Non-invasive prenatal testing for Down's syndrome (NIPT). Available: http://www.arc-uk.org/tests-explained/down-s- syndrome-screening/non-invasive-prenatal-testing-for-down-s-syndrome. Accessed 2013 Sep 30.
17. Wald NJ, Bestwick JP (2013) Incorporating DNA sequencing into current prenatal screening practice for Down's Syndrome. PLoS ONE 8: e58732.
18. Garfield SS, Armstrong SO (2012) Clinical and cost consequences of incorporating a novel non-invasive prenatal test into the diagnostic pathway for fetal trisomies. J Managed Care Med 15; 34-41.
19. Song K, Musci J, Caughey AB (2013) Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in hi-risk women based on a US population. J Matern Fetal Neonatal Med 26: 1180-1185.
20. Ohno M, Caughey AB (2013) The role of non-invasive prenatal testing as a diagnostic versus a screening tool - a cost-effectiveness analysis. Prenat Diagn 33: 630-635.
21. Cuckle H, Benn P, Pergament E (2013) Maternal cfDNA screening for Down syndrome - a cost sensitivity analysis. Prenat Diagn 33: 636-642.
22. NHS Fetal Anomaly Screening Programme (2012) Decision planning tool. Available: http://fetalanomaly.screening.nhs.uk/ costforscreeningstategies#fileid11456. Accessed 2013 Sep 30.
23. NHS Choices (2013). Tests for Down's syndrome. Available: http://www.nhs.uk/conditions/pregnancy-and-baby/pages/screening-amniocentesis- downssyndrome.aspx #close. Accessed 2014 Feb 6.
24. ONS (2010) Live births in England and Wales by characteristics of mother 2010. Available: http://www.ons.gov.uk/ons/publications/re-reference-tables. html?edition =tcm%3A77-230704. Accessed 2013 Sep 30.
25. Morris JK, Mutton DE, Alberman E (2002) Revised estimates of the maternal age specific live birth prevalence of Down's Syndrome. J Med Screening 9: 2-6. (Pubitemid 34327134)
26. Rowe R, Puddicombe D, Hockley C, Redshaw M (2008) Offer and uptake of prenatal screening for Down syndrome in women from different social and ethnic backgrounds. Prenat Diagn 28: 1245-1250.
27. Chitty LS, Hill M, White H, Wright D, Morris S (2012) Non-invasive prenatal testing for aneuploidy - ready for prime time? Am J Obstet Gynecol 206: 269-275.
28. Wright D (2009) DQASS: detection rates and false positive rates for first and second trimester Down's syndrome screening tests. Plymouth: Down's Syndrome Screening Quality Assurance Support Service (DQASS).
29. Bray I, Wright D (1998) Estimating the spontaneous loss of Down's syndrome fetuses between the times of chorionic villus sampling, amniocentesis and live birth. Prenat Diagn 18: 1045-1054. (Pubitemid 28497965)
30. Gilbert RE, Augood C, Gupta R, Ades AE, Logan S, et al. (2000) Cost-effectiveness and safety effectiveness of first and second trimester screening strategies for Down syndrome. London: Systematic Reviews Training Unit, Centre for Epidemiology and Biostatistics, University of London.
31. Wald NJ, Rodeck CH, Hackshaw AK, Walters J, Chitty LS, et al. (2003) First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 10: 56-104. (Pubitemid 36734906)
32. Wald NJ, Kennard A, Hackshaw A, McGuire A (1998) Antenatal screening for Down's syndrome. London: NHS R&D Health Technology Assessment (HTA) Programme. Health Technol Assess 2: 1-124.
33. Gray JAM, Ward P (2004) National Downs Syndrome Screening Programme for England: A Handbook for Staff (Version 2.0). London: UK National Screening Committee Programme Directorate.
34. Morris JK (2011) The National Down Syndrome Cytogenetic Register for England and Wales: 2010 Annual Report. London, United Kingdom: Queen Mary University of London, Barts and The London School of Medicine and Dentistry.
35. HESonline. Maternity data 2010-11. Available: http://www.hesonline.nhs. uk/Ease/servlet/ContentServer?siteID =1937&categoryID =1815. Accessed 2013 Sep 30.
36. Department of Health (2011) NHS Reference costs 2008-2009: Appendix NSRC01 - NHS Trust Reference Cost Schedules. London, United Kingdom: Crown; 2011 Jan 13. Report No: 15423, 16211.
37. Lewis C, Hill M, Silcock S, Chitty L (2013) Non-invasive prenatal testing for Down's Syndrome - pregnant women's views and likely uptake. Public Health Genomics 16: 223-232.
38. Chetty S, Garabedian MJ, Norton ME (2013) Uptake of non-invasive prenatal testing (NIPT) in women following positive aneuploidy screening. Prenat Diagn 33: 542-546.
39. Chitty LS, Kagan KO, Molina FS, Waters JJ, Nicolaides KH (2006) Fetal nuchal translucency scan and early prenatal diagnosis of chromosomal abnormalities by rapid aneuploidy screening: observational study. BMJ 332: 452-455.
40. Kagan KO, Chitty LS, Cicero S, Eleftheriades M, Nicolaides KH (2007) Ultrasound findings before amniocentesis in selecting the method of analysing the sample. Prenat Diagn 27: 34-39. (Pubitemid 46144338)